In a failing initial NNRTI-based regimen, the preferred option for second-line treatment is a boosted PI combined with 2 NRTIs.

• 获得性和交叉性耐药率很高。基于当前文献，指南和一线耐药突变率等资料，推荐在决定二线治疗组合前，进行基因型或表型耐药检测。